Ian C. Odland

Ian C. Odland

Auto-generated profile, based on publicly available information

Ian C. Odland

Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in Neurosurgery
Verified
Journal Article
Open access
SMStavros Matsoukas
Stavros Matsoukas
RFRui Feng
Rui Feng
DFDenzel E. Faulkner
Denzel E. Faulkner
IOIan C. Odland
Ian C. Odland
JDJohn Durbin
John Durbin
BRBenjamin I. Rapoport
Benjamin I. Rapoport
BACKGROUND AND OBJECTIVES: Preoperative embolization is used as an endovascular adjunct to surgical resection of meningiomas. However, there is no standardized system to assess the efficacy or extent of embolization during the embolization procedure. We sought to establish a purely angiographic grading system to facilitate consistent reporting of the outcome of meningioma embolization and to characterize the anatomic and other features of meningiomas that predict the degree of devascularization achieved through preoperative embolization. METHODS: We identified patients with meningiomas who underwent preoperative cerebral angiography and subsequent resection between 2015 and 2021. Demographic, clinical, and imaging data were collected in a research registry. We defined an angiographic devascularization grading scale as follows: grade 0 for no embolization, 1 for partial embolization, 2 for majority embolization, 3 for complete external carotid artery embolization, and 4 for complete embolization. RESULTS: Eighty consecutive patients were included, 60 of whom underwent preoperative tumor embolization (20 underwent angiography with an intention to treat but ultimately not embolization). Embolized tumors were larger (59.0 vs 35.9 cc; P = .03). Gross total resection, length of stay, and complication rates did not differ among groups. The distribution of arterial feeders differed significantly across tumors in a location-specific manner. Both the tumor location and the identity of arterial feeders were predictive of the extent of embolization. Anterior midline meningiomas were associated with internal carotid (ophthalmic, ethmoidal) supply and lower devascularization grades (P = .03). Tumors fed by meningeal feeders (convexity, falcine, lateral sphenoid wing) were associated with higher devascularization grades (P < .01). The procedural complication rate for tumor embolization was 2.5%. CONCLUSION: Angiographic outcomes can be graded to indicate the extent of tumor embolization. This system may facilitate consistency of reported angiographic results. In addition, arterial feeders vary in a manner predicted by tumor location, and these patterns correlate with typical degrees of devascularization achieved in those tumor locations.

4 May 2023 in World Neurosurgery
Verified
Journal Article
Closed access
CRChristina P Rossitto
Christina P Rossitto
IOIan C. Odland
Ian C. Odland
HOHolly Oemke
Holly Oemke
DCDanna Cruz
Danna Cruz
RKRoshini Kalagara
Roshini Kalagara
CKChristopher P. Kellner
Christopher P. Kellner

28 November 2022 in World Neurosurgery
Verified
Journal Article
Closed access
BSBraxton R. Schuldt
Braxton R. Schuldt
RKRoshini Kalagara
Roshini Kalagara
SCSusmita Chennareddy
Susmita Chennareddy
IOIan C. Odland
Ian C. Odland
MDMargaret H. Downes
Margaret H. Downes
CKChristopher P. Kellner
Christopher P. Kellner

19 January 2025 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
PDF file
IOIan Odland
Ian Odland
KLKayla J Liu
Kayla J Liu
DWDylan Wu
Dylan Wu
KYKurt A Yaeger
Kurt A Yaeger
LALuis C Ascanio
Luis C Ascanio
CKChristopher Kellner
Christopher Kellner
Background Appropriate management of spontaneous intracerebral hemorrhage (ICH) and intraventricular hemorrhage (IVH) requires rapid, accurate volume estimation. Viz.AI has developed an artificial intelligence (AI)-powered ICH calculation tool that may improve existing methods. Methods Adult patients presenting to a large healthcare system between December 2015 and December 2021 with spontaneous ICH greater than 10mL and within 72 hours since ictus were analyzed for hematoma volume. mABC/2 (modified ABC/2) was measured by a board-certified neurosurgeon. Semi-autonomous segmentation (SAS) was performed by a trained medical student on 3D Slicer, adjudicated by a board-certified neurosurgeon and used as a surrogate ground-truth volume. Results 139 CTs met inclusion criteria. Mean ICH volume via ground-truth SAS was 47.69±27.19 mL. Mean ICH volume difference between SAS and AI and SAS and mABC/2 was 4.77±4.06 mL and 8.36±9.48 mL, respectively (p<0.01). Bland-Altman plots yielded AI and SAS limits of agreement between −4.45 and 13.18 mL, and mABC/2 and SAS limits of agreement between −21.35 and 27.02 mL. The average absolute difference between IVH volume yielded by SAS and AI was 3.26±3.55 mL. Bland-Altman plots yielded IVH volume limits of agreement between −7.48 mLand 10.47 mL. AI was 94.6% sensitive and 94.0% specific for detecting IVH in the presence of ICH. The average time-to-volume for SAS and AI was 424±208 and 151±49.7 s (P<0.01), respectively. Conclusion Viz.AI is more accurate than mABC/2, and more rapid than SAS. The combination of speed and accuracy makes Viz.AI viable for clinical decision-making and clinical trial use.

7 June 2023 in World Neurosurgery
Verified
Journal Article
Closed access
VVVikram Vasan
Vikram Vasan
THTrevor A. Hardigan
Trevor A. Hardigan
BYBrandon Yeshoua
Brandon Yeshoua
MDMargaret H. Downes
Margaret H. Downes
MAMuhammad Ali
Muhammad Ali
SMShahram Majidi
Shahram Majidi

24 September 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IOIan C. Odland
Ian C. Odland
JBJoseph Borrello
Joseph Borrello
LFLayla Fattah
Layla Fattah
TWTyree D. Williams
Tyree D. Williams
KCKevin D. Costa
Kevin D. Costa
JGJanice Gabrilove
Janice Gabrilove
The Targeted HealthcaRe InnoVation & Entrepreneurship (THRIVE) Fellowship was created to bridge the gap between healthcare professionals, who often lack experience in technology development and entrepreneurship, and engineers or technology experts, who may not fully understand clinical needs. This eight-month extracurricular program introduces medical and graduate students to the process of health technology innovation. Fellows form multidisciplinary teams to identify and address an unmet clinical need, following Biodesign principles. The program consists of three phases: (1) introduction to healthcare innovation and foundational skills; (2) team formation, mentor selection, and customer discovery; and (3) solution prototyping, pitching, and business plan development. A retrospective analysis of the 2022–2023 cohort evaluated participant demographics, subjective outcomes (Likert-scale surveys on skill acquisition and program satisfaction), and objective metrics (e.g., milestones completed, funds raised, technology disclosures). Descriptive statistics and paired t-tests for pre-post comparisons were used in the analysis. Of the 56 applicants, 29 were accepted, and 20 completed the program. Fellows rated overall satisfaction at 4.45/5, with 85% planning to incorporate healthcare innovation into their future careers. On average, teams met 10.4 of 12 milestones, raised $10,250 in additional funds (in addition to the $5,000 fellowship grant), and filed multiple technology disclosures. Fellows reported significant gains in key innovation skills (p = 1.3E-5) and spent an average of 7.4 hours per week on their projects. The THRIVE Fellowship fosters interdisciplinary collaboration, practical skill development, and a heightened commitment to healthcare innovation. Early successes include strong participant satisfaction, measurable skill acquisition, and substantial external funding. Future program refinements will focus on expanded mentor engagement, enhanced skill-building resources, and long-term tracking of career outcomes. This model may serve as a scalable approach to training future clinicians and researchers in healthcare technology innovation.